E-Rad Solutions

E-Rad Solutions is a biotechnology company specializing in the development of targeted alpha therapies (TAT) and advanced radiochemistry solutions. The company focuses on optimizing the delivery of alpha-emitting isotopes, such as Lead-212, using proprietary chelator technologies designed to enhance stability and targeting precision. Founded by leading radiochemists from the University of Iowa, E-Rad Solutions supports the oncology pipeline by developing novel radiopharmaceuticals for indications like metastatic melanoma. In addition to its internal research, the company provides specialized services in radiopharmaceutical production, isotope processing, and regulatory support. Their platform aims to bridge the gap between early-stage radiochemistry research and clinical application in the growing field of nuclear medicine.